Patents by Inventor Guillaume LAPOINTE

Guillaume LAPOINTE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for preparing bis-tetrahydroisoquinoline-containing compounds
    Patent number: 10781213
    Abstract: (?)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: September 22, 2020
    Assignee: California Institute of Technology
    Inventors: Brian M. Stoltz, Eric R. Welin, Scott C. Virgil, Pamela Tadross, Gerit M. Pototschnig, Aurapat (Fa) Ngamnithiporn, Kenji Negoro, Guillaume Lapointe, Max Klatte, Christopher Haley, Christian Gruenanger, Emil Glibstrup, Christopher Gilmore, Kevin McCormack Allan
  • Methods for Preparing Bis-Tetrahydroisoquinoline-Containing Compounds
    Publication number: 20200157102
    Abstract: (?)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided.
    Type: Application
    Filed: November 22, 2019
    Publication date: May 21, 2020
    Inventors: Brian M. Stoltz, Eric R. Welin, Scott C. Virgil, Pamela Tadross, Gerit M. Pototschnig, Aurapat (Fa) Ngamnithiporn, Kenji Negoro, Guillaume Lapointe, Max Klatte, Christopher Haley, Christian Gruenanger, Emil Glibstrup, Christopher Gilmore, Kevin McCormack Allan
  • Methods for preparing bis-tetrahydroisoquinoline-containing compounds
    Patent number: 10526334
    Abstract: (?)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: January 7, 2020
    Assignee: California Institute of Technology
    Inventors: Brian M. Stoltz, Eric R. Welin, Scott C. Virgil, Pamela Tadross, Gerit Maria Pototschnig, Aurapat (Fa) Ngamnithiporn, Kenji Negoro, Guillaume Lapointe, Max Klatte, Christopher Haley, Christian Gruenanger, Emil Glibstrup, Christopher Gilmore, Kevin McCormack Allan
  • Methods for Preparing Bis-Tetrahydroisoquinoline-Containing Compounds
    Publication number: 20190048009
    Abstract: (?)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided.
    Type: Application
    Filed: July 18, 2018
    Publication date: February 14, 2019
    Inventors: Brian M. Stoltz, Eric R. Welin, Scott C. Virgil, Pamela Tadross, Gerit Maria Pototschnig, Aurapat (Fa) Ngamnithiporn, Kenji Negoro, Guillaume Lapointe, Max Klatte, Christopher Haley, Christian Gruenanger, Emil Glibstrup, Christopher Gilmore, Kevin McCormack Allan
  • TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS
    Publication number: 20180318311
    Abstract: This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof that are useful as antibacterial agents. The compounds are useful as inhibitors of bacterial gyrase activity and of bacterial infections, and have the structure of Formula (I): as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 8, 2018
    Inventors: Guillaume LAPOINTE, Wosenu MERGO, Heinz Ernst MOSER, Alexey RIVKIN, Colin Keith SKEPPER, Sarah Louise Williams
  • Isoxazole hydroxamic acid compounds as LpxC inhibitors
    Patent number: 10029994
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: July 24, 2018
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Ann Marie Madera, Zachary Kevin Sweeney
  • ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS
    Publication number: 20180030004
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: October 9, 2017
    Publication date: February 1, 2018
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Ann Marie MADERA, Zachary Kevin SWEENEY
  • Isoxazole hydroxamic acid compounds as LpxC inhibitors
    Patent number: 9815804
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: November 14, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Ann Marie Madera, Zachary Kevin Sweeney
  • Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
    Patent number: 9718792
    Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: August 1, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume LaPointe, Patrick Lee, Zachary Kevin Sweeney
  • ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LpxC INHIBITORS
    Publication number: 20170174640
    Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: March 9, 2017
    Publication date: June 22, 2017
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Patrick LEE, Zachary Kevin SWEENEY
  • Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
    Patent number: 9637482
    Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: May 2, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Patrick Lee, Zachary Kevin Sweeney
  • ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS
    Publication number: 20170088525
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Ann Marie MADERA, Zachary Kevin SWEENEY
  • ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LpxC INHIBITORS
    Publication number: 20170029415
    Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 2, 2017
    Applicant: Novartis AG
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Patrick LEE, Zachary Kevin SWEENEY
  • Isoxazole hydroxamic acid compounds as LpxC inhibitors
    Patent number: 9549916
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: January 24, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Ann Marie Madera, Zachary Kevin Sweeney
  • ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS
    Publication number: 20160166548
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Applicant: Novartis AG
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Ann Marie MADERA, Zachary Kevin SWEENEY